simvastatin + pravastatin

Simvastatin + pravastatin is a combination of two statin medications, both of which are HMG-CoA reductase inhibitors. These drugs work by competitively inhibiting the enzyme HMG-CoA reductase in the liver, which is responsible for catalyzing an early step in cholesterol biosynthesis. By blocking this enzyme, both simvastatin and pravastatin reduce endogenous cholesterol production, leading to lower levels of total cholesterol, LDL-cholesterol (bad cholesterol), and triglycerides while increasing HDL-cholesterol (good cholesterol). Both agents are used to treat hyperlipidemia and reduce cardiovascular risk including myocardial infarction and stroke. Simvastatin is known for its effectiveness at lowering LDL but has more drug interactions due to its metabolism via CYP3A4; pravastatin has fewer drug interactions as it is not significantly metabolized by CYP enzymes[1][3][5].